Optimizing drug discovery through investigative toxicology: Current and future trends
A think tank meeting organized by the Center for Alternatives to Animal Testing - Europe (CAAT-Europe)
Time: 10-12 July 2017
Venue: Hotel Belvedere Ranco (Lago Maggiore) Italy
Outline:
"Investigative Toxicology" (INV TOX) within the safety assessment strategies focuses on
mechanisms behind adverse outcomes, e.g. in the pharmaceutical sector on mechanisms
behind adverse drug effects. In the course of product (e.g. drugs) development, aims also at
early-stage identification of candidates toxic to human consumers (e.g. patients). Thus, the
implementation of INV TOX implies the reduction of recruited animals, e.g. at different
levels of drug development in the pharmaceutical industry.
The think tank on INV TOX hosted by CAAT-Europe and 14 Europe-based investigative
toxicology experts from 14 multi-national pharmaceutical industries (Investigative
Toxicology Leader (ITL) Forum), involves also experts from academia, other sectors and
regulatory bodies. The think tank is to address regulatory perspectives, current gaps,
shortcomings and pitfalls of INV TOX. Furthermore predictive features, validation criteria,
transferability and quality criteria are to be discussed in this think tank.